Christina Charles-Schoeman

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 20

Top Topics

Rheumatoid Arthritis

Ankylosing Spondylitis

Top Venues

Rheumatology and therapy

Annals of the rheumatic diseases

Rheumatology international

This page only lists publications with an associated author ORCID identifier.

Publications

Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Gary G Koch, Steven Ytterberg, Edward Nagy, Hyejin Jo, Kenneth Kwok, Carol A Connell, Karim Richard Masri, Arne Yndestad
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD open 10 (2) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Gary G Koch, Steven Ytterberg, Edward Nagy, Hyejin Jo, Kenneth Kwok, Carol A Connell, Karim Richard Masri, Arne Yndestad
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD open 10 (2) (2024)
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, Ernest H S Choy, Daniel E Furst, Jiri Vencovsky, Anthony G Wilson, Gerd-Rüdiger R Burmester, Derek Coombs, Sara K Penn, Nasser Khan, Jillian B Yee, Kassim Rahawi, Iain B McInnes
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and therapy 11 (1) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, Ernest H S Choy, Daniel E Furst, Jiri Vencovsky, Anthony G Wilson, Gerd-Rüdiger R Burmester, Derek Coombs, Sara K Penn, Nasser Khan, Jillian B Yee, Kassim Rahawi, Iain B McInnes
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and therapy 11 (1) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Gary G Koch, Steven Ytterberg, Edward Nagy, Hyejin Jo, Kenneth Kwok, Carol A Connell, Karim Richard Masri, Arne Yndestad
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD open 10 (2) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Gary G Koch, Steven Ytterberg, Edward Nagy, Hyejin Jo, Kenneth Kwok, Carol A Connell, Karim Richard Masri, Arne Yndestad
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD open 10 (2) (2024)
Maya H Buch, Deepak L Bhatt, Christina Charles-Schoeman, Jon T Giles, Ted Mikuls, Gary G Koch, Steven Ytterberg, Edward Nagy, Hyejin Jo, Kenneth Kwok, Carol A Connell, Karim Richard Masri, Arne Yndestad
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study. RMD open 10 (2) (2024)
Elizabeth Dente, Christina Charles-Schoeman
Itch but no rash in dermatomyositis? Treatment of heat-induced pruritic pain syndrome. Rheumatology (Oxford, England) (2024)
Roy M Fleischmann, Sebastian Meerwein, Christina Charles-Schoeman, Bernard G Combe, Stephen Hall, Nasser Khan, Kyle M Carter, Heidi S Camp, Andrea Rubbert-Roth
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD open 10 (3) (2024)
Christina Charles-Schoeman, Jon T Giles, Nancy E Lane, Ernest H S Choy, Daniel E Furst, Jiri Vencovsky, Anthony G Wilson, Gerd-Rüdiger R Burmester, Derek Coombs, Sara K Penn, Nasser Khan, Jillian B Yee, Kassim Rahawi, Iain B McInnes
Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years. Rheumatology and therapy (2024)
Christina Charles-Schoeman, Jennifer Wang, Ani Shahbazian, Holly Wilhalme, Jenny Brook, Gurjit S Kaeley, Buzand Oganesian, Ami Ben-Artzi, David A Elashoff, Veena K Ranganath
Power doppler ultrasound signal predicts abnormal HDL function in patients with rheumatoid arthritis. Rheumatology international (2023)
Roy Fleischmann, Jeffrey R Curtis, Christina Charles-Schoeman, Eduardo Mysler, Kunihiro Yamaoka, Christophe Richez, Hannah Palac, Deanne Dilley, Jianzhong Liu, Sander Strengholt, Gerd-Rüdiger R Burmester
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme. Annals of the rheumatic diseases (2023)
Sangmee Sharon Bae, Emmanuelle Faure-Kumar, Kathie G Ferbas, Jennifer Wang, Ani Shahbazian, Linh Truong, Howard Yang, Maureen McMahon, John D FitzGerald, Christina Charles-Schoeman
Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin. Rheumatology international (2023)
Christina Charles-Schoeman, Ernest H S Choy, Iain B McInnes, Eduardo Mysler, Peter Nash, Kunihiro Yamaoka, Ralph Lippe, Nasser Khan, Anna K Shmagel, Hannah Palac, Jessica Suboticki, Jeffrey R Curtis
MACE and VTE across upadacitinib clinical trial programmes in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. RMD open 9 (4) (2023)
Christina Charles-Schoeman, Maya H Buch, Maxime Dougados, Deepak L Bhatt, Jon T Giles, Steven R Ytterberg, Gary G Koch, Ivana Vranic, Joseph Wu, Cunshan Wang, Kenneth Kwok, Sujatha Menon, Jose L Rivas, Arne Yndestad, Carol A Connell, Zoltán Szekanecz
Risk of major adverse cardiovascular events with tofacitinib versus tumour necrosis factor inhibitors in patients with rheumatoid arthritis with or without a history of atherosclerotic cardiovascular disease: a post hoc analysis from ORAL Surveillance. Annals of the rheumatic diseases (2022)
Jeffrey I Weitz, Zoltán Szekanecz, Christina Charles-Schoeman, Ivana Vranic, Burak Sahin, Sara A Paciga, Zhenyu Wang, Craig Hyde, David A Martin
Biomarkers to predict risk of venous thromboembolism in patients with rheumatoid arthritis receiving tofacitinib or tumour necrosis factor inhibitors. RMD open 8 (2) (2022)